Sökning: "blood biomarkers"

Visar resultat 16 - 20 av 382 avhandlingar innehållade orden blood biomarkers.

1. 16. Neurodegenerative Biomarkers in Healthy Elderly - with special reference to the preclinical pattern of biological and cognitive markers for Alzheimer’s disease

   Författare :Erik Stomrud; Klinisk minnesforskning; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; cerebral blood flow; EEG; phosphorylated tau protein; amyloid beta protein; tau protein; cerebrospinal fluid; biomarkers; preclinical Alzheimer s disease; Alzheimer s disease; MCI; dementia; SPECT; memory; cognition; early diagnosis; control groups;

   Sammanfattning : Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by tau and amyloid brain pathology. With the gradual degeneration of neurons, cognitive symptoms will arise and the affected individual will eventually develop AD dementia. LÄS MER

3. 17. Proteomic strategies for blood biomarker development in rare dystrophinopathies

   Författare :Camilla Johansson; Cristina Al-Khalili Szigyarto; Ola Söderberg; KTH; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; Duchenne muscular dystrophy; Becker muscular dystrophy; proteomics; affinity-proteomics; biomarkers; DIA-MS; SRM-MS; immunoassay; suspension bead arrays; Duchenne muskeldystrofi; Becker muskeldystrofi; proteomik; affinitetsproteomik; biomarkörer; DIA-MS; SRM-MS; immunoassay; suspension bead array; Biotechnology; Bioteknologi;

   Sammanfattning : Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are two rare genetic disorders of the family dystrophinopathy. They are both caused by the lack of, or reduced production of, the protein dystrophin. LÄS MER

4. 18. Ischemic Stroke Outcomes - Analyses of Protein and Genetic Biomarkers

   Författare :Annie Pedersen; Göteborgs universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Stroke; Prognosis; Biomarkers; Genetics; Genome-Wide Association Study;

   Sammanfattning : The overall aim of this thesis was to identify novel biomarkers for ischemic stroke outcomes. The specific aims were to test the hypotheses that circulating concentrations of hemostatic biomarkers predict the long-term post-stroke risk of recurrent vascular events/death (paper I) and/or cognitive impairment (paper II) and that circulating concentrations of a marker of neuronal damage (neurofilament light chain, NfL) predict post-stroke functional and neurological outcomes (paper III) as well as to identify genetic variants associated with post-stroke functional outcome through a genome wide association study (GWAS) approach (paper IV). LÄS MER

5. 19. Psoriatic arthritis: a complex disease : analyses on genetic and serological biomarkers and of comorbidity

   Författare :Kristina Juneblad; Gerd-Marie Alenius; Solbritt Rantapää-Dahlqvist; Lars-Erik Kristenssen; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Psoriatic Arthritis; genetics; inflammasomes; polymorphisms; biomarkers; disease expression; disease activity; cardiovascular diseases; mortality; epidemiology;

   Sammanfattning : Psoriatic Arthritis (PsA) is a heterogonous inflammatory arthritis associated with psoriasis. The disease leads to inflammation of peripheral joints, axial skeleton and/or enthesites, and can result in severe destruction of affected joints. LÄS MER

7. 20. Pharmacometric Evaluation of Biomarkers to Improve Treatment in Oncology

   Författare :Ida Netterberg; Lena Friberg; Mats Karlsson; Elisabet I. Nielsen; Henrik Lindman; Amit Roy; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; Biomarkers; Oncology; Population PKPD Modeling; NONMEM; Farmaceutisk vetenskap; Pharmaceutical Science;

   Sammanfattning : Cancer is a family of many different diseases with substantial heterogeneity also within the same cancer type. In the era of personalized medicine, it is desirable to identify an early response to treatment (i.e., a biomarker) that can predict the long-term outcome with respect to both safety and efficacy. LÄS MER